Lung Cancer

Study shows promise for elderly lung cancer patients

Published in Cancer Weekly, June 24th, 2003

Data presented at the annual meeting of the American Society of Clinical Oncology showed that elderly patients with advanced non-small cell lung cancer (NSCLC) who received Taxotere (docetaxel) Injection Concentrate with a platinum compound had improvement in median survival compared to the combination of vinorelbine and cisplatin, another standard first-line regimen in this patient group.

"This study shows that performance status trumps age; the fit elderly patients do as well as younger patients receiving combination platinum-based therapy for advanced non-small cell lung cancer," said Corey Langer, MD, director, thoracic and head & neck medical oncology, Fox Chase...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry